@article{
author = "Kostadinović, Jelena and Popadić, Višeslav and Klašnja, Slobodan and Klisić, Aleksandra and Kotur-Stevuljević, Jelena and Andrić, Zoran and Zdravković, Marija",
year = "2023",
abstract = "The clinical efficacy of chemotherapy, as a recognized therapeutic approach for malignant
diseases, usually has certain limitations due to its cardiotoxicity (CT) and consequent
cardiomyopathy, or even heart failure. CT
is defined as any cardiac injury connected with
oncology treatment, whether it is chemo
-, radio
-, targeted or immunotherapy, or cancer by itself,
and it represents a great challenge for clinicians in everyday practice. A wide spectrum of factors
related t
o chemotherapy (type of drug, dose during each cycle, cumulative dose, schedule, method
of application, combination with other cardiotoxic drugs or association with radiotherapy) and
patient characteristics (age, presence of cardiovascular risk factors, pr
evious cardiovascular
disease) are the determining factors that influence the frequency of CT. Imaging methods for
morphological and functional monitoring of the heart muscle are used for monitoring CT. The
quest for diagnostic tools for early CT detection
is of great significance. In line with this, the
measurement of some cardiac biomarkers has found its place in clinical settings as an early
determinant of myocardial injury. Therefore, in this review article, special attention will be paid
to certain wel
l-established, as well as certain novel cardiac biomarkers, and their role in
recognizing asymptomatic CT, in order to gain deeper insight into their diagnostic utility., Klinička efikasnost hemioterapije, kao priznatog terapeutskog pristupa malignim
bolestima, obično ima određena ograničenja zbog svoje kardiotoksičnosti (KT), te posledične
kardiomiopatije, pa čak i srčane insuficijencije. KT se definiše kao svaka povreda miokarda
povezana s lečenjem raka, uzimajući u obzir hemioterapiju, radioterapiju, biološku ili
imunoterapiju, kao i sam karcinom, te predstavlja veliki izazov za kliničare
u svakodnevnoj
praksi. Širok spektar faktora povezanih s hemioterapijom (vrsta leka, doza tokom svakog ciklusa,
kumulativna doza, raspored, način primene, kombinacija s drugim kardiotoksičnim lekovima ili
povezanost s radioterapijom) i karakteristike bolesnika (dob, prisutnost faktora kardiovaskularnog
rizika, prethodne kardiovaskularne bolesti), odlučujući su faktori koji utiču na učestalost KT. Za
praćenje KT koriste se radiološke metode za morfološko i funkcionalno praćenje srčanog mišića.
Potraga za dij
agnostičkim alatima za rano otkrivanje KT od velikog je značaja. U skladu s tim,
merenje nekih srčanih biomarkera kao rane determinante povrede miokarda našlo je svoje mesto
u kliničkim okruženjima. Stoga
će u ovom preglednom članku posebna pažnja biti po
sve
ć
ena
nekim dobro utvrđenim, kao i nekim novim srčanim biomarkerima, i njihovoj ulozi u
prepoznavanju asimptomatske KT, kako bi se stekao dublji uvid u njihovu dijagnostičku korisnost
i neželjene efekte lekova koji se primenjuju u terapiji karcinoma.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Cardiotoxicity: Importance of biomarkers, Kardiotoksičnost: Važnost biomarkera",
volume = "73",
number = "1",
pages = "1-16",
doi = "10.5937/arhfarm73-40534"
}